- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06047834
Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids
A Phase 2, Open-Label, Randomized, Controlled, Ascending Dose Cohort, Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids
A randomized, open-label, controlled, ascending dose cohort, PK, and safety study assessing standard of care (i.e., non-pharmacologic measures and morphine when indicated) with or without lofexidine for the treatment of opioid withdrawal symptoms in neonates due to intrauterine exposure to opioids, described as neonatal opioid withdrawal syndrome (NOWS) or neonatal abstinence syndrome (NAS).
This study has been designed to assess the pharmacokinetics (PK) and safety of the lofexidine in neonates experiencing NOWS. The effectiveness of lofexidine on the severity of NOWS will also be evaluated. Results from this study will be used to support dosing recommendations in neonates and to inform further studies in the pediatric patient population.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Medical Affairs
- Phone Number: 1-888-900-8796
- Email: medinfo@usworldmeds.com
Study Locations
-
-
West Virginia
-
Huntington, West Virginia, United States, 25701
- Recruiting
- Marshall Health
-
Contact:
- Todd Davies, PhD
- Email: daviest@marshall.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent obtained from the patient's parent or legally authorized representative(s) (LAR)/guardian(s) in accordance with local laws and Institutional Review Board (IRB) requirements.
- Infants <7 days of age at the time of randomization.
- Gestational age ≥35 weeks at birth.
- Minimum weight ≥1.8 kg at birth.
- Infant's mother is ≥18 years of age.
Intrauterine opiate exposure expected to contribute to NOWS symptoms, as determined by the Principal Investigator and supported by at least one of the following:
- Maternal history of opiate use during pregnancy as confirmed by diagnosis of opioid use disorder (OUD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), treatment for OUD, treatment with an opioid prescribed by a licensed physician or health care worker, documentation of opiate use in maternal medical record, and/or maternal self-reported opiate use;
- Positive maternal urine opiate screen during pregnancy or delivery; or
- Participant urine, meconium, or cord blood or tissue testing positive for opiate metabolites.
- Symptomatic with 2 consecutive scores ≥8 on the mFNAST at sites using the mFNAST OR at least one score ≥1 on the ESC assessment and with agreement from the clinical care team at sites using the ESC approach to care. Note: The study team should use the same NOWS scoring method (i.e., mFNAST or ESC assessment) to determine the patient's eligibility as is used to assess NOWS symptoms per the local standard of care.
- Can receive medications orally.
Exclusion Criteria:
- Patients who developed NOWS due to prolonged neonatal intensive care unit (NICU) analgesia and sedation therapy.
- Received treatment for NOWS, including morphine, methadone, buprenorphine, clonidine, or phenobarbital before screening/randomization.
- Prenatal exposure to an investigational drug, device, or biological agent other than investigational formulations of buprenorphine or methadone administered as part of treatment for maternal opioid dependence.
- Any anticipated or scheduled surgery during the patient's inpatient treatment for NOWS through approximately 30 days after completion of their treatment for NOWS (not including circumcision).
- Seizures, confirmed by EEG.
- mFNAST score ≥14.
- Two consecutive blood pressure measurements greater than 15 minutes apart with a systolic blood pressure <55 mm Hg.
- Two consecutive heart rate measurements <110 bpm more than 15 minutes apart.
- Clinically significant abnormal ECG at Screening in the judgment of the Principal Investigator, including a QTc interval >480 msec on a Screening ECG. Note: if the QTc interval meets the above criteria, the value may be confirmed by repeating the measurement twice, with each ECG obtained approximately 30-60 minutes apart, and the QTc interval confirmed by a pediatric cardiologist. If the pediatric cardiologist confirms the QTc interval is >480 msec based on two of the three ECGs, the patient will be excluded from participation. If the pediatric cardiologist confirms the QTc interval is ≤480 msec based on two of the three ECGs, the patient may be considered for study entry at the discretion of the Investigator in consultation with the pediatric cardiologist. Patients with a confirmed QTc >480 msec at Screening will be monitored per local standard of care, at least once daily, until the QTc resolves to within normal range. Patients not enrolled in the study will receive additional evaluation and care as clinically indicated.
Have clinically significant abnormal laboratory values on laboratory tests completed for clinical reasons, including laboratory values outside the normal range as determined by the local lab that would put the patient at undue risk, as determined by the Principal Investigator, including either of the following:
- Hematocrit values of <40%
- Platelet count <100,000/μL
- Requiring sustained treatment with IV fluids or supplemental oxygen. Note: Patients with a transient need for IV fluids or supplemental oxygen may be considered for inclusion in the study at the Investigator's discretion.
- Any congenital malformations or acute medical illness, condition, or clinical finding that, in the opinion of the Principal Investigator and/or the Sponsor, would put the patient at undue risk for study participation or interfere with the patient's ability to complete the study, including concerns related to medication administration or patient survival.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control
All participants will receive non pharmacologic interventions per the local standard of care (i.e.
non-pharmacologic measures and morphine when indicated).
|
Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine.
Subjects randomized to standard of care without lofexidine wilt receive non-pharmacologic measures and morphine when indicated.
|
Experimental: Low Dose Lofexidine
Drug: Lofexidine (LX2) All participants will receive standard of care and be administered 32 µg/kg/day.
The daily dose will be divided into 8 equal doses administered every 3 hours.
Lofexidine will be tapered to discontinuation.
|
Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine.
Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 escalating dose levels (in terms of lofexidine base): low dose, mid dose, or high dose.
|
Experimental: Mid Dose Lofexidine
Drug: Lofexidine (LX2) All participants will receive standard of care and be administered 52 µg/kg/day.
The daily dose will be divided into 8 equal doses administered every 3 hours.
Lofexidine will be tapered to discontinuation.
|
Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine.
Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 escalating dose levels (in terms of lofexidine base): low dose, mid dose, or high dose.
|
Experimental: High Dose Lofexidine
Drug: Lofexidine (LX2) All participants will receive standard of care and be administered 80 µg/kg/day.
The daily dose will be divided into 8 equal doses administered every 3 hours.
Lofexidine will be tapered to discontinuation.
|
Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine.
Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 escalating dose levels (in terms of lofexidine base): low dose, mid dose, or high dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentrations following single dose and repeated lofexidine administration in participants
Time Frame: Day 1 through Day 7
|
To evaluate the pharmacokinetic (PK) parameters of lofexidine granules for reconstitution
|
Day 1 through Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Single dose and steady-state maximum concentrations
Time Frame: Day 1 through Day 7
|
To evaluate the pharmacokinetic (PK) parameters of lofexidine granules for To evaluate the pharmacokinetic (PK) parameters of lofexidine granules for reconstitution
|
Day 1 through Day 7
|
Extent of accumulation (i.e., Accumulation Ratio [AR]) with repeated dosing
Time Frame: Day 1 through Day 7
|
To evaluate the pharmacokinetic (PK) parameters of lofexidine granules for reconstitution
|
Day 1 through Day 7
|
Examination of dose proportionality
Time Frame: Day 1 through Day 7
|
To evaluate the pharmacokinetic (PK) parameters of lofexidine granules for reconstitution
|
Day 1 through Day 7
|
Estimation of apparent clearance
Time Frame: Day 1 through Day 7
|
To evaluate the pharmacokinetic (PK) parameters of lofexidine granules for reconstitution
|
Day 1 through Day 7
|
Estimation of apparent volume of distribution
Time Frame: Day 1 through Day 7
|
To evaluate the pharmacokinetic (PK) parameters of lofexidine granules for reconstitution
|
Day 1 through Day 7
|
Treatment emergent adverse events (TEAEs)
Time Frame: Day 1 through 30 day follow-up
|
To evaluate the safety of lofexidine during administration in infants experiencing NOWS
|
Day 1 through 30 day follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Substance Withdrawal Syndrome
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Narcotic Antagonists
- Sympatholytics
- Clonidine
- Lofexidine
Other Study ID Numbers
- USWM-LX2-2001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Withdrawal (Disorder)
-
Spark Biomedical, Inc.CompletedNovel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid WithdrawalOpioid-use Disorder | Opioid WithdrawalUnited States
-
Spark Biomedical, Inc.CompletedOpioid-use Disorder | Opioid WithdrawalUnited States
-
USWM, LLC (dba US WorldMeds)SuspendedOpioid Withdrawal (Disorder)United States
-
University of VermontNational Institute on Drug Abuse (NIDA); Johns Hopkins University; University... and other collaboratorsCompletedOpioid-use Disorder | Neonatal Abstinence Syndrome | Opioid Withdrawal | Neonatal Opioid Withdrawal SyndromeUnited States
-
Evon Medics LLCNational Institute on Drug Abuse (NIDA); Howard University; Family and Medical... and other collaboratorsRecruitingWithdrawal Symptoms | Craving | Opioid Use Disorder, Moderate | Opioid Use Disorder, Severe | Negative AffectivityUnited States
-
Johns Hopkins UniversityDalio FoundationCompletedOpioid Use Disorder | Opioid Withdrawal | Opioid CravingUnited States
-
Johns Hopkins UniversityRecruitingAnxiety | Opioid Use Disorder | Opioid Withdrawal | Opioid CravingUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingOpioid Use Disorder | Opioid Withdrawal | Opioid CravingUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Yale University; Clinilabs, Inc.; BioXcel...RecruitingOpioid Use Disorder | Opioid WithdrawalUnited States
-
Mayo ClinicUSWM, LLC (dba US WorldMeds)Completed
Clinical Trials on Standard of Care without Lofexidine
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Colorado...CompletedDisproportionate Shape | Expanded Fat PadsUnited States
-
Läkarexpressen ABLund University; Region Skane; Region Halland; Västra GötalandsregionenCompleted
-
NRG OncologyNational Cancer Institute (NCI); Alliance for Clinical Trials in Oncology; Eastern... and other collaboratorsRecruitingHER2-positive Breast CancerUnited States, Puerto Rico
-
Walter Reed National Military Medical CenterCompletedFunctional ConstipationUnited States
-
Germans Trias i Pujol HospitalUnknownEmergence Delirium | Preoperative Anxiety | Maladaptive Postoperative BehaviorSpain
-
Min SuNot yet recruitingPostoperative Pulmonary ComplicationsChina
-
University Hospital, LilleCompletedVentral HerniaFrance
-
Sharp HealthCareGE Healthcare; Sharp Mary Birch Hospital for Women & NewbornsCompletedPremature Infant | Extreme Prematurity | Extremely Low Birth WeightUnited States
-
National Taiwan University Hospital Hsin-Chu BranchUnknownSepsis | Peripheral Artery Disease | Diagnosis | Peripheral Artery OcclusionTaiwan
-
Legacy Health SystemCompletedBreast CancerUnited States